S095029
Sponsors
Institut de Recherches Internationales Servier, Servier Bio-Innovation LLC
Conditions
MSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction CancerNon-small Cell Lung Cancer (NSCLC)Solid Tumor
Phase 1
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
CompletedNCT05162755
Start: 2021-10-15End: 2026-05-05Updated: 2026-05-12
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Active, not recruitingNCT06116136
Start: 2024-08-31End: 2027-08-01Updated: 2026-04-03
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Active, not recruitingNCT06162572
Start: 2024-08-07End: 2027-07-01Updated: 2026-08-11